Navigation Links
Agenus to Participate at Two Upcoming Immuno-Oncology Conferences
Date:3/24/2017

LEXINGTON, Mass., March 24, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced participation at the following conferences:

  • The 7th Annual William Blair and Maidstone Life Sciences conference "Cancer Immunotherapy Conference" at the Apella, Event Space Alexandria Center in New York, NY. Agenus will participate in three sessions:
    • March 29 at 9:40 am: Robert B. Stein, M.D., Ph.D., President, R&D will present at a session titled "AutoSynVaxTM and PhosphoSynVaxTM: Next Generation Neoepitope Heat Shock Protein Vaccines" followed by a panel discussion on therapeutic vaccines.
    • March 30 at 10:40 am: Dr. Stein will present at a session titled "Next Generation Immunomodulatory Antibodies: Optimizing Therapeutic Impact."
    • March 30 at 12:00 pm: Jean-Marie Cuillerot, M.D., Chief Medical Officer, will participate in the lunch panel titled "Challenges in Immuno-Oncology Drug Development." 
  • Jefferies Immuno-Oncology Summit at the Boston Harbor Hotel in Boston, MA. Agenus will participate in two sessions:
    • March 30 at 3:00 pm: Jennifer Buell, Ph.D., VP, Global Integrated R&D Operations, will participate in a panel titled "Vaccines – Is There a Future?"
    • March 30 at 3:45 pm: Nick Wilson, Ph.D., Executive Director, Immuno-modulatory Drug Discovery, will participate in a panel titled "Checkpoints - Which Target has the Best Chances of Success?"

About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing a number of combination approaches that leverage a broad repertoire of antibody therapeutics and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is based in Lexington, MA. For more information, please visit www.agenusbio.com; information that may be important to investors will be routinely posted on our website.

Forward Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the upcoming presentations. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Contact:

Agenus Inc.
Michelle Linn, 781-674-4541
michelle.linn@agenusbio.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/agenus-to-participate-at-two-upcoming-immuno-oncology-conferences-300428924.html


'/>"/>
SOURCE Agenus Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. How These Biotech Stocks are Faring? -- Agenus, Tokai Pharma, Eleven Biotherapeutics, and Rexahn Pharma
2. Agenus to Present at the Jefferies 2016 London Healthcare Conference
3. Thad Bench of Benchworks to Participate in 8th Annual Life Science Chief Executive Officer Forum
4. Relmada Therapeutics to Participate in BIO CEO and Investor Conference
5. Exact Sciences to participate in Leerink Partners Global Healthcare Conference
6. Symic Bio to Participate in the 2017 East/West CEO Conference
7. Mannin Research to Participate at ARVO 2016 Meeting
8. Leading Fertility Experts Participate in CCRM Networks Inaugural Scientific Conference
9. Shire to Participate at the Cowen 36th Annual Healthcare Conference
10. Eiger to Participate in Cowen & Company 2016 Health Care Conference
11. Cerapedics to Participate in Canaccord Genuitys Musculoskeletal Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/11/2019)... ... January 11, 2019 , ... Drawing on over 22 ... January 22, 2019 at 2:30pm EST will explore some of the key lessons that ... using one vendor vs. using multiple vendors, and find out how to ensure that ...
(Date:1/8/2019)... , ... January 08, 2019 , ... The American ... grant recipients were named by a selection committee made up of industry leaders identified ... The Career Development grants are mentored awards created to support ASGCT members designing transformative ...
(Date:1/4/2019)... ... January 03, 2019 , ... Calidi Biotherapeutics, ... cancer, today announced the founding of a scientific and medical advisory board (SMAB). ... key leaders in the Immuno-Oncology field. The founding members of Calidi Biotherapeutics SMAB ...
(Date:12/18/2018)... ... December 18, 2018 , ... USDM Life ... the life sciences industry, unveiled a completely redesigned website at http://www.usdm.com . ... browsing experience for their valued clients and business partners. , The website ...
Breaking Biology Technology:
(Date:12/18/2018)... POWAY, Calif. (PRWEB) , ... December 18, 2018 , ... ... Dressage. He has been competing for many years however in 2006, he had ... a trot. It was determined that he suffered from cartilage degeneration in his ...
(Date:12/13/2018)... ... December 13, 2018 , ... Study Protocol Summary of QC Procedure , 1 ... first assessment performed at the site., 3 - Three photos captured with Apple iPad ... in BOX., 5 - Photos moved to eAdjudication® and submitted to Reviewers., 6 - ...
(Date:12/13/2018)... , ... December 12, 2018 , ... ... advancement of regenerative cellular therapy, has announced the launch of Maxx-Cell, the world's ... a gold standard approach of aspirating a patients autologous bone marrow cells. Maxx™-Cell ...
Breaking Biology News(10 mins):